Please login to the form below

Not currently logged in
Email:
Password:

Astellas signs CNS deal with BioFocus

Astellas Pharma is to focus on central nervous system (CNS) disorders with the help of BioFocus

Astellas Pharma has signed a collaboration agreement with BioFocus focused on discovering novel targets in the field of central nervous system disorders.  

Under the agreement, BioFocus will utilise its SilenceSelect target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.  

Dr Chris Newton, managing director of BioFocus, said: "We are delighted to support Astellas Pharma in its research. Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology."

12th May 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Why people join a clinical trial
To understand why people decide to take part in clinical trials, you first need to understand how people make decisions....
Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...